Can outcomes get any better for Receptos Inc.? That's certainly one question investors, analysts and even company officials were thinking after Receptos disclosed top-line phase II data on lead compound RPC1063 in ulcerative colitis (UC) after Monday's market close. Read More
Amgen Inc.'s moves into the biosimilar space drew attention during the company's business review meeting, which followed the release of investor-pleasing third quarter financial results that showed the company beating estimates and included higher guidance for the full year's earnings. Read More
LONDON – Advent Venture said it will stick to its strategy of making large investments in early and midstage biotechs with its second dedicated life sciences fund, which just closed at £145.5 million (US$235 million). Read More
DUBLIN – Bristol-Myers Squibb Co. is paying $50 million up front and could pay another $425 million to acquire F-Star Alpha Ltd. and its human epidermal growth factor receptor 2 (HER2)-targeted therapy, FS102. Read More
SHANGHAI – Biotech acquisitions are increasingly becoming a part of the Chinese outbound investment story. This time around, up and comer Zhejiang Betta Pharmacuetical Co. has made a commitment to invest $20 million in equity in Xcovery Inc., of West Palm Beach, Fla. Read More
A U.S. court cleared a major generic threat to The Medicines Co.'s top-seller, Angiomax (bivalirudin), ruling Monday that Mylan Inc.'s abbreviated new drug application (ANDA) infringed on a patent protecting the anticoagulant through 2028. Read More
HONG KONG – Chinese researchers have demonstrated that grafted neural stem cells directly release dopamine into the damaged striata of rat brains in vivo and partially rescued a model of Parkinson's disease (PD), providing proof of concept for the feasibility of that technique for treating PD in humans. Read More
SUZHOU, China – The China growth story continues to buoy the life science industry, even in the face of challenging headwinds of change. That was the message from PwC experts who extensively surveyed executives and innovators across device, service, venture capital and pharma, many of whom were in the room for the recent collegial ChinaBio Leadership Retreat in Changshu. Read More
Araim Pharmaceuticals Inc., of Tarrytown, N.Y., said it was awarded FDA fast track designation for lead compound ARA290 for treating sarcoidosis-associated small fiber neuropathy (SFN). Read More
Alnylam Pharmaceuticals Inc., of Cambridge, Mass., and The Medicines Co. (MDCO), of Parsippany, N.J., filed a clinical trial application with the U.K. Medicines and Healthcare Products Regulatory Agency to initiate a phase I trial with ALN-PCSsc to treat hypercholesterolemia. The subcutaneously administered RNAi therapeutic uses Alnylam's enhanced stabilization chemistry (ESC)-GalNAc-siRNA conjugate delivery platform and targets the gene proprotein convertase subtilisin/kexin type 9, or PCSK9, which affects the metabolism of low-density lipoprotein cholesterol (LDL-C). Read More
CSL Behring, of King of Prussia, Pa., said its Swiss affiliate and Enable Injections LLC, of Franklin, Ohio, signed a long-term development agreement for a drug delivery system. Read More
Hikma Pharmaceuticals plc, of London, reported that it received a warning letter last week from the FDA stemming from an inspection of its manufacturing facility in Portugal earlier this year. Read More
